NYSE:AMAM Ambrx Biopharma (AMAM) Stock Forecast, Price & News $11.66 +0.33 (+2.91%) (As of 09/20/2023 ET) Add Compare Share Share Today's Range$11.18▼$12.2050-Day Range$9.30▼$15.8452-Week Range$0.38▼$16.86Volume617,055 shsAverage Volume1.89 million shsMarket Capitalization$723.04 millionP/E RatioN/ADividend YieldN/APrice Target$22.57 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Ambrx Biopharma MarketRank™ ForecastAnalyst RatingModerate Buy2.86 Rating ScoreUpside/Downside93.6% Upside$22.57 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews Sentiment0.48Based on 12 Articles This WeekInsider TradingAcquiring Shares$19.63 M Bought Last QuarterProj. Earnings GrowthGrowingFrom ($1.24) to ($1.17) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.24 out of 5 starsMedical Sector382nd out of 962 stocksBiological Products, Except Diagnostic Industry51st out of 156 stocks 3.4 Analyst's Opinion Consensus RatingAmbrx Biopharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $22.57, Ambrx Biopharma has a forecasted upside of 93.6% from its current price of $11.66.Amount of Analyst CoverageAmbrx Biopharma has only been the subject of 4 research reports in the past 90 days. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for AMAM. Previous Next 0.0 Dividend Strength Dividend YieldAmbrx Biopharma does not currently pay a dividend.Dividend GrowthAmbrx Biopharma does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for AMAM. Previous Next 3.0 News and Social Media Coverage News SentimentAmbrx Biopharma has a news sentiment score of 0.48. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 12 news articles for Ambrx Biopharma this week, compared to 3 articles on an average week.Search Interest31 people have searched for AMAM on MarketBeat in the last 30 days. This is an increase of 520% compared to the previous 30 days.MarketBeat Follows4 people have added Ambrx Biopharma to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Ambrx Biopharma insiders have bought more of their company's stock than they have sold. Specifically, they have bought $19,625,013.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 0.64% of the stock of Ambrx Biopharma is held by insiders.Percentage Held by Institutions77.28% of the stock of Ambrx Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Ambrx Biopharma are expected to grow in the coming year, from ($1.24) to ($1.17) per share.Price to Book Value per Share RatioAmbrx Biopharma has a P/B Ratio of 3.82. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Ambrx Biopharma (NYSE:AMAM) StockAmbrx Biopharma Inc., a clinical-stage biologics company, discovers and develops engineered precision biologics using its proprietary expanded genetic code technology platform. The company's lead product candidate is ARX788, an anti-HER2 antibody-drug conjugate (ADC), which is investigated in various clinical trials for the treatment of breast cancer, gastric/gastroesophageal junction cancer, and other solid tumors, including ongoing Phase 2/3 clinical trials for the treatment of HER2-positive metastatic breast cancer and gastric cancer. It is also developing two earlier-stage product candidates, including ARX517, an anti-PSMA ADC, which is in a Phase 1 clinical trial for the treatment of prostate cancer and other solid tumors; and ARX305, an anti-CD70 ADC in investigational new drug-enabling studies for the treatment of renal cell carcinoma and other cancers. In addition, the company is developing ARX102, an immuno-oncology IL-2 pathway agonist to stimulate the patient's own immune system by targeting the ß and gamma receptors on the cytotoxic T cell. Ambrx Biopharma Inc. has collaborations with Bristol Myers Squibb Company; AbbVie Inc.; BeiGene; Sino Biopharmaceutical Co., Ltd.; NovoCodex; and Elanco Animal Health. The company was incorporated in 2003 and is headquartered in La Jolla, California.Read More AMAM Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AMAM Stock News HeadlinesSeptember 21, 2023 | americanbankingnews.comCormorant Asset Management, Lp Buys 751,233 Shares of Ambrx Biopharma Inc. (NYSE:AMAM) StockSeptember 21, 2023 | americanbankingnews.comCormorant Asset Management, Lp Acquires 1,401,505 Shares of Ambrx Biopharma Inc. (NYSE:AMAM) StockSeptember 21, 2023 | Edge On The Street (Ad)Is Gold Really Boring?Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks. September 21, 2023 | americanbankingnews.comAmbrx Biopharma (NYSE:AMAM) Shares Gap Up Following Insider Buying ActivitySeptember 19, 2023 | americanbankingnews.comAmbrx Biopharma (NYSE:AMAM) Stock Rating Reaffirmed by Cantor FitzgeraldSeptember 19, 2023 | americanbankingnews.comAmbrx Biopharma Inc. (NYSE:AMAM) Given Average Rating of "Moderate Buy" by BrokeragesSeptember 18, 2023 | finance.yahoo.comAmbrx to Participate in the Cantor Fitzgerald Global Healthcare ConferenceSeptember 17, 2023 | americanbankingnews.comAmbrx Biopharma (NYSE:AMAM) Shares Gap Down to $9.94September 21, 2023 | Edge On The Street (Ad)Is Gold Really Boring?Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks. September 15, 2023 | nasdaq.comGoldman Sachs Maintains Ambrx Biopharma Inc - ADR (AMAM) Neutral RecommendationSeptember 15, 2023 | americanbankingnews.comAmbrx Biopharma (NYSE:AMAM) Price Target Raised to $10.00 at The Goldman Sachs GroupSeptember 13, 2023 | markets.businessinsider.comWhere Ambrx Biopharma Stands With AnalystsSeptember 13, 2023 | americanbankingnews.comAmbrx Biopharma (NYSE:AMAM) Now Covered by Analysts at BTIG ResearchSeptember 5, 2023 | finance.yahoo.comAmbrx to Present at the Baird and Morgan Stanley Global Healthcare ConferencesAugust 31, 2023 | msn.comAmbrx Biopharma Has Surged 524% This Year. But It Could Just Be Getting Started.August 21, 2023 | msn.comPromising Developments In Ambrx's Engineered Precision BiologicsAugust 16, 2023 | msn.comCantor Fitzgerald Reiterates Ambrx Biopharma Inc - ADR (AMAM) Overweight RecommendationAugust 12, 2023 | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Ambrx Biopharma (AMAM), QuidelOrtho (QDEL) and Aveanna Healthcare Holdings (AVAH)August 1, 2023 | msn.comRBC Capital Initiates Coverage of Ambrx Biopharma Inc - ADR (AMAM) with Outperform RecommendationAugust 1, 2023 | finance.yahoo.comAmbrx Appoints Renu Vaish, M.Sc., as Chief Regulatory Officer to Lead Regulatory AffairsJuly 31, 2023 | markets.businessinsider.comUnique ADC Constructs Boost Ambrx Biopharma's Profile: Analyst Sees Optimistic OutlookJuly 28, 2023 | finance.yahoo.comAmbrx to Present Preliminary ARX517 First-in-Human Safety, Efficacy, and Pharmacokinetics Data at ESMO 2023July 19, 2023 | msn.comAmbrx Biopharma wins FDA fast track tag for prostate cancer therapyJuly 19, 2023 | finance.yahoo.comFDA Grants Fast Track Designation for Ambrx’s ARX517 for the Treatment of Metastatic Castration-Resistant Prostate CancerJuly 15, 2023 | sg.finance.yahoo.comAmbrx Biopharma Inc. (AMAM)June 28, 2023 | finance.yahoo.comAmbrx Announces Closing of $75 Million Market Priced Registered OfferingJune 21, 2023 | au.finance.yahoo.comAMAM - Ambrx Biopharma Inc.See More Headlines Receive AMAM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ambrx Biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address AMAM Company Calendar Last Earnings8/09/2023Today9/20/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNYSE:AMAM CUSIPN/A CIK1836056 Webambrx.com Phone858-875-2400FaxN/AEmployees79Year FoundedN/APrice Target and Rating Average Stock Price Forecast$22.57 High Stock Price Forecast$30.00 Low Stock Price Forecast$10.00 Forecasted Upside/Downside+93.6%Consensus RatingModerate Buy Rating Score (0-4)2.86 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio13.28 Quick Ratio13.28 Sales & Book Value Annual Sales$7.40 million Price / Sales97.71 Cash FlowN/A Price / Cash FlowN/A Book Value$3.05 per share Price / Book3.82Miscellaneous Outstanding Shares62,010,000Free Float61,613,000Market Cap$723.04 million OptionableNot Optionable Beta-2.66 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesMr. Daniel J. O'Connor J.D. (Age 58)CEO, Pres & Director Comp: $509.94kMs. Sonja Nelson CPA (Age 50)Chief Financial Officer Comp: $1.18MMr. Andrew P. Aromando (Age 54)Chief Operating Officer Dr. Ying J. Buechler Ph.D.Chief Technology OfficerDr. Shawn Shao-Hui Zhang Ph.D.Chief Scientific Officer & GM of ChinaMr. Jared KellySr. VP, Gen. Counsel & Corp. Sec.Mr. Robert AzzaraVP of Human CapitalDr. Sandra Aung Ph.D.Chief Clinical OfficerMs. Renu Vaish M.Sc. (Age 56)Chief Regulatory Officer More ExecutivesKey CompetitorsCabaletta BioNASDAQ:CABAAdaptimmune TherapeuticsNASDAQ:ADAPNovavaxNASDAQ:NVAXAllogene TherapeuticsNASDAQ:ALLOEditas MedicineNASDAQ:EDITView All CompetitorsInsiders & InstitutionsCormorant Asset Management, LpBought 751,233 shares on 9/18/2023Total: $6.94 M ($9.24/share)Cormorant Asset Management, LpBought 1,401,505 shares on 9/15/2023Total: $12.68 M ($9.05/share)Holocene Advisors LPBought 913,754 shares on 8/15/2023Ownership: 1.480%Point72 Asset Management L.P.Bought 349,938 shares on 8/15/2023Ownership: 0.567%HighVista Strategies LLCBought 153,431 shares on 8/15/2023Ownership: 0.248%View All Insider TransactionsView All Institutional Transactions AMAM Stock - Frequently Asked Questions Should I buy or sell Ambrx Biopharma stock right now? 7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Ambrx Biopharma in the last year. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" AMAM shares. View AMAM analyst ratings or view top-rated stocks. What is Ambrx Biopharma's stock price forecast for 2023? 7 analysts have issued 12-month target prices for Ambrx Biopharma's stock. Their AMAM share price forecasts range from $10.00 to $30.00. On average, they predict the company's share price to reach $22.57 in the next twelve months. This suggests a possible upside of 93.6% from the stock's current price. View analysts price targets for AMAM or view top-rated stocks among Wall Street analysts. How have AMAM shares performed in 2023? Ambrx Biopharma's stock was trading at $2.27 on January 1st, 2023. Since then, AMAM shares have increased by 413.7% and is now trading at $11.66. View the best growth stocks for 2023 here. How were Ambrx Biopharma's earnings last quarter? Ambrx Biopharma Inc. (NYSE:AMAM) released its earnings results on Wednesday, August, 9th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.28) by $0.23. The firm had revenue of $1.12 million for the quarter, compared to analyst estimates of $1.50 million. What ETFs hold Ambrx Biopharma's stock? ETFs with the largest weight of Ambrx Biopharma (NYSE:AMAM) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR).Virtus LifeSci Biotech Clinical Trials ETF (BBC). When did Ambrx Biopharma IPO? (AMAM) raised $126 million in an initial public offering on Friday, June 18th 2021. The company issued 7,000,000 shares at $17.00-$19.00 per share. Goldman Sachs, BofA Securities and Cowen acted as the underwriters for the IPO. What is Ambrx Biopharma's stock symbol? Ambrx Biopharma trades on the New York Stock Exchange (NYSE) under the ticker symbol "AMAM." Who are Ambrx Biopharma's major shareholders? Ambrx Biopharma's stock is owned by many different retail and institutional investors. Top institutional shareholders include Cormorant Asset Management LP (15.57%), Commodore Capital LP (5.14%), VR Adviser LLC (4.50%), Holocene Advisors LP (1.48%), ExodusPoint Capital Management LP (0.86%) and Point72 Asset Management L.P. (0.57%). View institutional ownership trends. How do I buy shares of Ambrx Biopharma? Shares of AMAM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Ambrx Biopharma's stock price today? One share of AMAM stock can currently be purchased for approximately $11.66. How much money does Ambrx Biopharma make? Ambrx Biopharma (NYSE:AMAM) has a market capitalization of $723.04 million and generates $7.40 million in revenue each year. How can I contact Ambrx Biopharma? The official website for the company is ambrx.com. The company can be reached via phone at 858-875-2400 or via email at ir@ambrx.com. This page (NYSE:AMAM) was last updated on 9/21/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ambrx Biopharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.